News | January 27, 2023
Dr. Reddys Laboratories Q3 FY2023 consolidated PAT up to Rs. 1243.9 Cr
The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022
The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022
The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Medical Tourism will boost India’s economy
Asthma patients are more likely to have an asthma attack during winter
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
USFDA issued issued Form 483 with nine observations, which will be addressed within stipulated time.
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
Subscribe To Our Newsletter & Stay Updated
